🇺🇸

US SEC Filing Intelligence

· daily

All NASA Contracts — May 04, 2026

NASA's sole contract in this period obligated $351,035,113 to ALCYON TECHNICAL SERVICES (ATS) JV, LLC, a fully civilian award (0/1 defense-related) at Goddard Space Flight Center for systems engineering services. This 8(a) competed set-aside, cost-plus-fixed-fee contract spans 2015-2023 with $246,907,027 outlayed to date and $7,385,356,524 in subawards across 2690 transactions. The dominant agency theme is NASA civilian space R&D (NAICS 541712, PSC R425), with neutral signal strength averaging 3.0/10 and low materiality (2/10). Highest-conviction signal is low pricing risk on steady execution progress. Key watch item: remaining $104,128,086 outlays and post-2023-11-30 contract end compliance.

1 total filings
· daily

S&P 500 Technology Sector SEC Filings — May 04, 2026

Across 28 filings in the USA S&P 500 Technology stream (broadly including adjacent sectors like comms, medtech, and SPACs), Q1 2026 results show mixed trends: revenue declines in Cogent Communications (-3.2% YoY to $239M) and off-net (-17% YoY), offset by EBITDA margin expansion (+2.1% YoY to 29.3%) and wavelength surge (+90.8% YoY); Apple Hospitality REIT RevPAR +2.2% YoY but net income -11.3% YoY. Strong AGM outcomes at Intuitive Surgical (10/10 proposals passed, $5B buyback authorization) and Cogent (directors >90% FOR, CEO 1M RSU perf award) signal management alignment and conviction. SPAC activity peaks with AParadise merger approval but 19.6M share redemptions (93% of quorum), flagging dilution risks; Genco tender offer at $23.50/share adds M&A momentum. Capital allocation favors returns: Cogent $0.02/share dividend, Apple Hospitality $242.5M buyback remaining and forward hotel buys ($65.5M Q4'27, $143.7M Q2'28). 13F filings reveal fund conviction in tech-adjacent like TTM Technologies ($45.8M Emerald), NVIDIA/Apple (Paradiem), MSFT/AMZN (Camden). Portfolio-level: improving liquidity (Snow Lake cash +606% YoY) amid losses, neutral appointments (Block CAO, Ducommun director), setting up catalysts in tenders/AGMs.

15 high priority 13 medium 28 total filings
· daily

Nasdaq 100 Stocks SEC Filings — May 04, 2026

Across 30 SEC filings from NASDAQ-100 related entities on May 4, 2026, overarching themes include mixed Q1 2026 financial results with revenue growth in niche players (e.g., OneMeta +4710% YoY, Metallus +10% YoY) offset by declines in established names (Cogent service rev -3.2% YoY, Apple Hospitality net income -11.3% YoY), strong shareholder approvals at annual meetings (Gilead, Intuitive Surgical, Cogent >90% FOR on key proposals), and active capital markets with Meta's $25B debt raise and Genco's $23.50/share tender offer. Portfolio-level trends show margin resilience in some (Cogent EBITDA margin + to 29.3%, Metallus EBITDA +39% YoY) amid operating losses, with REITs like Apple Hospitality and Sun Communities signaling acquisition pipelines and presentations. M&A/SPAC activity is elevated (AParadise merger approval with 19.6M shares redeemed, Genco takeover), while capital allocation favors buybacks/dividends (Apple Hospitality $242.5M remaining, Cogent $0.02 dividend). Neutral 13F filings indicate passive institutional holding, and positive governance updates (board appointments, equity plans) dominate. Implications: Selective growth opportunities in high-flyers, caution on margin pressures, catalysts from conferences and deal closings.

14 high priority 16 medium 30 total filings
· daily

S&P 500 Financials Sector SEC Filings — May 04, 2026

Across 50 SEC filings from May 4, 2026, primarily S&P 500 Financials but spanning insurers, REITs, banks, SPACs, and broader sectors, key themes include robust M&A/SPAC activity (e.g., GNL-Modiv accretive merger, multiple IPO S-1/A amendments), mixed Q1 2026 results with aggregate revenue growth of ~6% YoY in reporting companies (e.g., Berkshire +4.4%, Loews +1.4%, CNA +1.4%) but volatile net income (Berkshire +119% outlier, CNA -23%, Loews -9%), and insurance underwriting pressures (combined ratios worsening ~380bps YoY at CNA/Loews). Capital allocation shows steady dividends (CNA $0.48/share, Superior $0.14/share) amid buybacks (Berkshire $235M treasury stock) and debt reductions (Superior LT debt -8% QoQ). Institutional 13Fs reveal tech-heavy portfolios (e.g., Crystal Rock top Alphabet/Meta, Yahav QQQ semis), signaling conviction in growth sectors. Forward-looking data flags lowered guidance (Norwegian Net Yield -3-5%) and catalysts like Cabaletta data H1/H2 2026. Portfolio-level trends: 8/12 earnings reporters saw revenue +YoY but 6/12 net income declines; M&A premiums average 17% (GNL-Modiv). Implications: Favor accretive deals and strong earners like Berkshire; caution insurers on reserves/loss ratios amid positive BVPS trends.

28 high priority 22 medium 50 total filings
· daily

S&P 500 Consumer Staples Sector SEC Filings — May 04, 2026

Across 50 SEC filings from the USA S&P 500 Consumer Staples intelligence stream (broadly encompassing food, beverages, household, personal care with adjacent industrials/energy), overarching themes include mixed Q1 2026 earnings with revenue growth averaging +8% YoY in reporting firms (e.g., Krystal +32%, Powell +6%) but frequent profit declines (-20% avg in mixed reporters like Exxon -46%, NCL EPS double but FY guidance cut) due to cost pressures, margin compression (~150 bps avg in 7/15 metrics), and working capital strains. M&A activity surges with accretive deals like GNL-Modiv ($535M, +4% AFFO, Q3 close) and Hubbell-NSI ($3B, +EPS 2026), signaling consolidation; capital returns robust via buybacks ($66M New Mountain, $548M Diamondback) and dividends (Great Elm 18% yield, SmartStop $1.60 ann.). Portfolio-level patterns show 6/10 mixed sentiment filings with NAV declines (e.g., New Mountain -5.2%, Great Elm -4%) amid unrealized losses, but positive catalysts in FDA approvals (ADMA) and order backlogs (Powell +33% to $1.8B). Implications: Favor M&A beneficiaries and capex raisers (Diamondback oil +5% FY guide) over guidance cutters (NCL yields -3-5%); sector faces margin headwinds but strong liquidity supports returns.

23 high priority 27 medium 50 total filings
· daily

S&P 500 Industrials Sector SEC Filings — May 04, 2026

Across 50 SEC filings from the USA S&P 500 Industrials stream (broadly encompassing aerospace, defense, machinery, transportation, construction, and adjacent sectors), overarching themes include mixed Q1 2026 earnings with 6/10 reporting companies showing revenue growth averaging +20% YoY (e.g., Biodesix +42%, Backblaze +11.7%) offset by declines in cyclicals like Boise Cascade (-2% sales YoY) and Cogent (-3.2% YoY), alongside accretive M&A in industrial real estate and positive capital raises/licensing in health-adjacent industrials. EBITDA margins expanded in 7/12 key filers (avg +200bps YoY, driven by cost controls at Boise +136% BMD EBITDA growth and Backblaze +800bps to 26%), signaling operational resilience amid softening demand from housing starts (-5% YoY). Capital allocation remains shareholder-friendly with $65.5M Boise buybacks, $548M Diamondback repurchases, and consistent dividends (e.g., Marzetti $0.12/share). Forward-looking catalysts cluster in Q2-Q3 2026, including merger closes, guidance realizations, and clinical data readouts. Institutional 13F snapshots (16/50 filings) reveal heavy tech/industrials tilts (e.g., Vertiv, BWX Tech), indicating conviction in infrastructure/AI themes. Most critical: Global Net Lease's $535M industrial acquisition (4% AFFO accretive, Q3 close) and Biodesix's 42% revenue surge with raised FY guidance, positioning select industrials for outperformance vs. sector peers.

16 high priority 34 medium 50 total filings
· daily

S&P 500 Energy Sector SEC Filings — May 04, 2026

S&P 500 Energy sector filings reveal mixed Q1 2026 performance, with ExxonMobil (XOM) posting 2.4% YoY revenue growth to $85.1B but a sharp 45.8% YoY net income drop to $4.2B due to higher costs and Energy Products losses, contrasting Hess Midstream's (HESM) stable results with Adjusted EBITDA up 2.6% YoY to $299.8M. Major M&A advances with Devon Energy (DVN) and Coterra (CTRA) merger overwhelmingly approved (98-99% votes), set to close ~May 7, enhancing scale in E&P. Leadership transitions signal continuity: XOM elects new Chief Accounting Officer effective July 1, Occidental (OXY) names COO Richard Jackson as CEO from June 1. Capital returns remain robust, with XOM deploying $9.2B on buybacks/dividends, HESM repurchasing $60M units/shares and hiking distributions 2.4% to $0.7792/share. Williams Companies (WMB) shows strong governance via AGM approvals (91-99% support). Non-energy filings like 13Fs and SPACs add neutral context but no sector impact. Overall, cost pressures challenge integrateds/midstream, but M&A catalysts and returns support resilience.

8 high priority 5 medium 13 total filings
· daily

US Material Events SEC 8-K Filings — May 04, 2026

Across 50 SEC filings from May 4, 2026, dominant themes include a surge in M&A activity (e.g., GNL's $535M acquisition of MDV, Lattice's $1.65B AMI deal, Ecovyst's INEOS purchase) and SPAC developments (e.g., Collective II $220M IPO, Blueport $1.2B SingAuto deal, Flag Ship termination), signaling robust dealmaking in industrials, tech, and SPACs despite one notable bankruptcy at SG Echo. Period-over-period trends show revenue growth in key reporters: Lattice +42.2% YoY, Ameresco +14% YoY, Sonos +8% YoY, GECC NII +13% QoQ, but mixed with NAV drops (GECC -4.1% QoQ, New Mountain -5.2% QoQ) and margin pressures (Ameresco gross margin 14% impacted by weather). Leadership changes abound (26/50 filings), mostly orderly transitions (e.g., Publix, Aura Biosciences, Hercules Capital) with positive sentiment, alongside biotech financings (Cabaletta $150M, Rein $50M) bolstering cash for trials. Capital allocation leans shareholder-friendly: GECC $0.25 dividend (18% yield), Intuitive $5B buyback increase, Track Group debt cut 63%. Forward-looking catalysts cluster in Q3 2026 (multiple closings) with biotech trial data into 2027. Portfolio-level: Industrials/REITs M&A accretive (GNL +4% AFFO), biotech optimistic on offerings/trials, but watch mixed financials and SPAC risks for volatility.

50 high priority 50 total filings
· daily

Dow Jones 30 Stocks SEC Filings — May 04, 2026

Across 50 SEC filings from the USA Dow Jones 30 intelligence stream (May 4, 2026 period), dominant themes include aggressive M&A in industrial/REIT space (GNL-Modiv $535M all-stock deal, 4% AFFO accretive, 17% premium), mixed Q1 2026 earnings with pharma/biotech revenue growth averaging +7-8% YoY (Evolus +7%, Vertex +8%) offset by declines in offshore drilling (-13% QoQ Valaris) and telecom (-3.2% YoY Cogent), and robust capital allocation via buybacks/repurchases (Indivior $175M ASR, Progressive $467M treasury shares). Institutional 13Fs (14 filings) reveal heavy tech concentration (e.g., NVIDIA, Amazon top holdings across Yahav, Triglav, Montaka), signaling sustained bull market conviction. Forward-looking data flags lowered guidance (Norwegian Cruise Net Yield -3-5%, EPS $1.45-1.79) amid demand softness, contrasted by reaffirmed targets (Evolus $327-337M revenue). Bankruptcies (Safe & Green, Spirit Aviation wind-down) highlight distress in niche industrials/aviation. Portfolio-level trends: 6/12 earnings filings show YoY revenue growth >5% but 4/12 with EBITDA/affo declines; capital returns strong in 5 firms (dividends, buybacks up YoY). Actionable: M&A catalysts in Q3 2026, watch biotech data readouts H1-H2.

14 high priority 36 medium 50 total filings
· daily

US SEC Filings Daily Market Digest — May 04, 2026

The May 4, 2026, SEC filings reveal a surge in IPO amendments (e.g., Cerebras, GMR Solutions, Odyssey Therapeutics, Liftoff Mobile, Fervo Energy) across AI, biotech, and EMS sectors, signaling robust capital market access amid high valuations ($115-125/share for Cerebras). M&A activity dominates industrials/REITs with Global Net Lease's $535M acquisition of Modiv Industrial (17% premium, 4% AFFO accretive, Q3 close), alongside SPAC deals like Blueport-SingAuto ($1.2B). Q1 2026 earnings show mixed results: revenue growth averaging +7% YoY (e.g., Berkshire +4.4%, NCLH +10%, Illumina +4.8%) but margin pressures in insurance (CNA combined ratio +380bps to 102.2%, Loews CNA down 23%) and widening biotech losses (Odyssey +15% YoY to $148.6M). 13F filings highlight persistent tech concentration (NVIDIA, MSFT, AAPL top holdings across filers like AMF, Triglav). Forward guidance includes cuts (NCLH FY Net Yield -3-5%) and positives (Cabaletta H1/H2 2026 data), with capital allocation favoring dividends (CNA $0.48) and debt reduction (Cushman partial redemption). Portfolio-level trends: 8/15 earnings filers grew revenues YoY but 6/8 showed NI declines; biotech sentiment mixed due to R&D ramps.

28 high priority 22 medium 50 total filings
· daily

S&P 500 Consumer Discretionary Sector SEC Filings — May 04, 2026

Across 50 filings in the S&P 500 Consumer Discretionary stream (with cross-sector exposure via REITs, food/retail, and industrials), sentiment is predominantly mixed (14/50), reflecting revenue growth averaging +12% YoY in 18 earnings reporters (e.g., Sterling +92%, L.B. Foster +24%, Tyson +4.4%) but offset by profitability challenges like impairments (Armada net loss worsened to $33.3M) and volume declines (FreightCar -33%, OneWater -8.5%). Guidance trends are resilient with 6 raises/reaffirmations (Armada FFO to $0.51-$0.55, Sterling EBITDA to $843-873M), signaling management conviction amid restructuring (e.g., Armada $562M portfolio sale, $700M debt paydown). Capital allocation favors shareholders via $24.1M buybacks (Armada), dividends (Tyson $0.48, Superior $0.14, SmartStop $1.60 annualized), and M&A approvals (Farmer Bros 86.9% yes). IPO activity (GMR, Liftoff, Fervo) and SPAC developments (Willow neutral, Flag Ship terminated) highlight deal flow risks/opportunities. Institutional 13Fs (11 filings) show stable heavy weighting in consumer/tech names like Costco, Amazon (e.g., Garrison top Costco $10M). Portfolio-level: Margin expansion in winners (Marzetti + to 23.6%) vs compression elsewhere; actionable now on raised guidance and near-term catalysts like May 15 Cushman redemption.

15 high priority 35 medium 50 total filings
· daily

S&P 500 Healthcare Sector SEC Filings — May 04, 2026

Across 50 filings in the USA S&P 500 Healthcare stream (with broader financial crossovers), mixed sentiment dominates healthcare/biotech names, with 4/7 key players (Twist, Vertex, Merck, Aura) showing YoY revenue growth averaging +12.8% (Twist +19%, Vertex +8%, Merck +4.9%) but widening net losses due to elevated R&D/SG&A (e.g., Twist net loss +12% YoY to $44M, Merck $4.2B loss from $8.5B acquisition charge), signaling heavy investment in pipelines amid 99% revenue plunge outlier at Akston Biosciences IPO. Capital allocation leans bullish with buybacks surging (Intuitive Surgical $5B authorization, Tidewater $500M, New Mountain $66M YTD +$50M more, Aura $39M repurchase), dividends steady (CNA $0.48, Corebridge $0.25), and share repurchases reflecting management conviction despite NAV declines (New Mountain -5.2% to $10.92). Leadership transitions positive in healthcare (Aura new CEO Natalie Holles, Edwards new CFO Doretta Mistras), while non-healthcare finance/insurance shows stable NII but margin pressures (CNA combined ratio +380bps to 102.2%, Loews net income -9%). Forward guidance largely raised/reiterated (Twist FY26 rev to $442-447M +17-19% growth, Vertex $12.95-13.1B), building H2 2026-2027 catalysts like Aura Phase 3 topline. 13F filings (9 total) reveal neutral institutional positioning with heavy ETF/tech tilts but healthcare exposure (e.g., Thermo Fisher, UnitedHealth). Portfolio-level: Healthcare growth intact but loss-making (avg gross margin +100bps at Twist), buybacks signal undervaluation, watch M&A (Corebridge-Equitable, Rallybio termination fee $50M). Actionable: Favor buyback-heavy medtech/biotech over plunging revenue IPOs.

17 high priority 33 medium 50 total filings
· daily

US Executive Compensation Proxy SEC Filings — May 04, 2026

Across these 10 DEF 14A proxy statements for US companies, a dominant theme is preparation for mid-June 2026 annual meetings, with 9/10 virtual and focused on routine governance items like director elections (all 10), say-on-pay advisory votes (8/10), and auditor ratifications (10/10), signaling stable board continuity amid executive compensation scrutiny. Financial highlights are sparse but reveal stark contrasts: National Vision Holdings stands out with FY2025 revenue +9.0% YoY to $1,987.5M, Adjusted Op Income +56.5% YoY to $102.5M (margin +5.2pp to 8.8%), and Adj EPS +53.8% YoY to $0.80, while STAAR Surgical reports a challenging FY2025 with slower growth and merger rejection but positive 2026 momentum from EVO+ exceeding expectations in China. Veeva Systems signals strong shareholder alignment via $2B buyback and engagement with 40% of shares, contrasting dilution risks in Wellgistics (blank check preferred) and Xos (plan expansion + note conversions >20% shares). Mixed/neutral sentiments prevail (7 neutral, 2 positive, 2 mixed), with no widespread insider trading or capital allocation shifts beyond Veeva's repurchase; portfolio-level trends show healthcare/tech firms prioritizing equity incentives amid governance enhancements like Helios' clawback policy. Market implications include low volatility from routine votes but alpha from outliers like National Vision's growth and STAAR's turnaround, with clustered catalysts in June 2026.

10 high priority 10 total filings
· daily

US IPO Pipeline SEC S-1 Filings — May 04, 2026

The IPO Pipeline stream features three S-1 filings dated May 4, 2026, dominated by dilutive resale registrations for Acurx Pharmaceuticals (two filings totaling ~2.95M shares) and a high-materiality SPAC IPO by Keystone Acquisition Corp ($250M base, up to $287.5M). No period-over-period financial trends (YoY/QoQ revenue/margins) are detailed, but pricing data reveals Acurx shares issued at low weighted average $3.07 post-Dec 2025 vs higher warrants ($7.25/$2.78), signaling share price pressure and funding desperation in biotech. Keystone's standard SPAC structure with founder shares at $0.003 highlights classic low-cost promotion potential. Overarching themes include biotech reliance on equity lines/warrants for working capital amid dilution risks (mixed/neutral sentiment), contrasted by resurgent SPAC activity. Critical implications: Acurx faces liquidity/price declines, while Keystone IPO could catalyze M&A hunting; portfolio-level pattern shows 2/3 filings as non-traditional 'IPOs' via resales, underscoring weak primary capital raise momentum.

3 high priority 3 total filings
· daily

Global High-Priority Regulatory Events — May 04, 2026

The 50 filings reveal a surge in high-priority events including positive insolvency resolutions (e.g., Embassy Developments quashing CIRP), a wave of IPO amendments in AI/tech/biotech (Cerebras, GMR Solutions, Fervo Energy), and active M&A/SPAC activity (GNL-Modiv merger, Blueport-SingAuto). Q1/FY2026 financials show mixed trends with average revenue growth of ~6-10% YoY across reporters (e.g., Berkshire +4.4%, Krystal +32%, National Vision +9%), but profitability volatile (Berkshire net earnings +119%, CNA -23%, Odyssey losses +15% YoY). Margin expansions in some (National Vision +520 bps) contrast compressions elsewhere, while capital returns include buybacks (Jagsonpal ₹40 Cr, Berkshire $235M treasury) and dividends. Indian filings highlight neutral board meetings and open offers amid insolvency risks, US-focused on IPOs/mergers with positive sentiment dominating (18/50 positive/mixed-positive). Portfolio-level: Industrials/real estate M&A bullish, biotech IPOs mixed on losses, no major insider selling patterns but leadership changes signal transitions. Implications: Near-term catalysts in earnings (May-Jun) and mergers offer alpha, watch delisting risks and trial readouts.

50 high priority 50 total filings
· daily

US Earnings Financial Results SEC Filings — May 04, 2026

Across 50 Q1 2026 US SEC filings, revenue growth was resilient with 38/50 companies reporting YoY increases averaging 12.5% (range 0.7%-2600%), driven by core operations, acquisitions, and international expansion, though profitability was volatile with 25 firms seeing net income declines due to impairments, higher costs, and one-offs. Margin trends mixed: gross margins expanded in 22 cases (avg +500bps in food/tech) but compressed in energy/insurance (avg -200bps). Capital allocation robust with $15B+ in dividends/buybacks (e.g., Progressive $8B dividend, Berkshire $236M buybacks), signaling management confidence amid $20B+ M&A spend. Biotech/pharma (12 firms) narrowed losses 40% avg on rev ramps, energy/oil (5 firms) faced input cost pressures (-30% NI avg), financials (8 firms) grew NII 8% avg with stable provisions. No major guidance changes noted, but forward capex/dividend hikes flag H2 catalysts; mixed sentiment (46/50) implies sector rotation opportunities in improving biotechs vs pressured cyclicals. Portfolio implication: overweight growth biotechs/financials, underweight energy amid OPEX inflation.

50 high priority 50 total filings
· daily

US SEC Trading Suspension Halt Orders — May 04, 2026

Both Hoth Therapeutics and Jaguar Health face severe Nasdaq delisting risks, with negative sentiment and high materiality (9-10/10), highlighting a pattern of compliance failures in the biotech sector on the Nasdaq Capital Market. Hoth received a bid price deficiency notice for 30 consecutive days below $1.00 (March 18-April 29, 2026), granting 180 days until October 27, 2026, to cure, while Jaguar, post a 1-for-35 reverse stock split on April 30, 2026, failed the 500,000 publicly held shares requirement (only 401,226 shares), adding to its bid price issues and triggering a May 8, 2026, response deadline to the Hearings Panel. No period-over-period financial trends, revenue growth, or margin data provided in filings, focusing purely on regulatory halts risks; no insider trading activity, capital allocation changes (beyond reverse split), or M&A noted. Cross-company comparison shows Jaguar's situation more acute (materiality 10/10 vs 9/10) due to recent reverse split failure, signaling portfolio-level distress in low-float biotechs. Market implications include potential trading suspensions, delistings, and heightened volatility, urging avoidance or short strategies for exposed positions.

2 high priority 2 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — May 04, 2026

Across 43 filings in the USA Corporate Distress & Bankruptcy stream, the dominant theme is proactive distress resolution through M&A (e.g., GNL-Modiv $535M all-stock deal, Assertio-Garda $153M tender), equity offerings (Cabaletta $150M, Rein $50M), and debt amendments/extensions (Track Group net debt -63% to 2.6x leverage, Alcoa maturity to 2028), offsetting outright distress like SG Echo Chapter 11 bankruptcy and Nasdaq delisting risks (Hoth, Jaguar). Period-over-period trends show resilient revenue growth in select names (Ameresco +14% YoY Q1 2026, Lattice +42% YoY Q1 revenue to $170.9M) but mixed profitability (Ameresco net loss widened to $18.3M YoY, Lattice op cash flow margin -10.1pp QoQ). Capital allocation leans toward deleveraging and shareholder alignment (Track Group PIPE + new board owning 75%, Turtle Beach $49M buybacks), with forward-looking catalysts clustered in Q2-Q3 2026 (multiple M&A closings, Modiv vote). Portfolio-level patterns reveal biotech/pharma heavy (10+ filings) pursuing financings amid dilution risks, industrials consolidating via acquisitions, and sparse insider sales but new director additions signaling conviction. Overall, signals point to turnaround opportunities outweighing pure bankruptcies, with 7/43 filings showing margin stability or gains (Lattice +100bps YoY gross margin). Market implication: Distressed assets trading at premiums in M&A (Modiv 17-28%, Garda 63% to unaffected), favoring event-driven strategies.

43 high priority 43 total filings
· daily

US Executive Officer Management Changes SEC — May 04, 2026

Across 45 filings in the USA Executive & Director Changes stream (33 new), a wave of 20+ CEO/CFO/executive transitions dominates, including 8 retirements/planned departures (e.g., Publix Executive Chairman, Occidental CEO, Exxon CAO, Pool Corp CEO, Adeia CEO) and 15+ appointments/promotions (e.g., Aura CEO, Hercules President/CFO, Edwards Lifesciences CFO from Viatris), signaling proactive leadership refreshes amid sector pressures. Financial trends where reported show mixed results: BDCs like New Mountain (NII flat YoY at $0.32/share, NAV -5% QoQ to $10.92) and Great Elm (NII +13% QoQ to $0.36/share but NAV -4% QoQ to $7.74) highlight portfolio volatility; Sonos Q2 rev +8% YoY to $282M with first positive EBITDA in 4 years; Pinterest Q1 rev +18% YoY to $1.008B but net loss widened to $74M. Capital allocation remains shareholder-friendly with repurchases (New Mountain $66M YTD +$50M auth, Great Elm 1% shares at 36% NAV discount, Intuitive $5B program increase) and dividends (Great Elm $0.25/share Q2, 18% yield). Positive sentiments in 60% of filings (e.g., hires with deep expertise), but mixed/neutral in departures; biotech hires (Aura, Pasithea, Tivic) tie to trial catalysts. Portfolio-level: Margin stability in consumer/tech offset by BDC NAV erosion; energy/retail transitions orderly. Implications: Opportunities in growth-oriented hires (biotech, semis), risks in BDC volatility and sudden CFO churn (5 cases).

45 high priority 45 total filings
· daily

US Bankruptcy Chapter 11 Insolvency SEC Filings — May 04, 2026

The single filing in the USA Bankruptcy & Insolvency stream highlights a major distress event for Olenox Industries Inc. (formerly Safe & Green Holdings Corp., SGBX), as its wholly-owned subsidiary SG Echo LLC filed voluntary Chapter 11 on April 28, 2026, in the Eastern District of Oklahoma, triggering a $4M loan default stay. No period-over-period financial trends are detailed, but the bankruptcy underscores underlying operational or liquidity pressures absent from prior disclosures. Parent company operations continue normally with the subsidiary operating as debtor-in-possession (DIP), suggesting contained impact but high materiality (10/10) and negative sentiment. Market implications include potential sharp equity downside, heightened volatility, and short-term trading opportunities in distressed assets. Portfolio-level pattern: isolated subsidiary restructuring amid broader insolvency watchlist, with no cross-filing comparisons available.

1 high priority 1 total filings